UnknownPhase 2NCT03608007

X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement

Studying Cap myopathy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Betta Pharmaceuticals Co., Ltd.
Principal Investigator
Shun Lu
PHD
Intervention
X-396 Capsule(drug)
Enrollment
69 enrolled
Eligibility
18 years · All sexes
Timeline
20182020

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03608007 on ClinicalTrials.gov

Other trials for Cap myopathy

Additional recruiting or active studies for the same condition.

See all trials for Cap myopathy

← Back to all trials